Bioporto A/S
CSE:BIOPOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bioporto A/S
CSE:BIOPOR
|
DK |
|
Alight Inc
NYSE:ALIT
|
US |
|
SciVision Biotech Inc
TWSE:1786
|
TW |
|
Top Shelf International Holdings Ltd
ASX:TSI
|
AU |
|
GSE Systems Inc
NASDAQ:GVP
|
US |
|
M
|
My EG Services Bhd
KLSE:MYEG
|
MY |
|
M
|
Mudanjiang Hengfeng Paper Co Ltd
SSE:600356
|
CN |
|
Cr Credit Agricole Mutuel Loire Hte Loir
PAR:CRLO
|
FR |
|
T
|
TC Energy Corp
NYSE:TRP
|
CA |
|
Empresa Distribuidora y Comercializadora Norte SA
NYSE:EDN
|
AR |
|
C
|
China-Singapore Suzhou Industrial Park Development Group Co Ltd
SSE:601512
|
CN |
|
SNL Bearings Ltd
BSE:505827
|
IN |
|
S
|
Shanghai Rendu Biotechnology Co Ltd
SSE:688193
|
CN |
|
MIC Electronics Ltd
NSE:MICEL
|
IN |
|
K
|
Kennametal India Ltd
NSE:KENNAMET
|
IN |
|
Rifa Co Ltd
KRX:000760
|
KR |
|
Amcor PLC
NYSE:AMCR
|
UK |
Bioporto A/S
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
